Holen Sie sich die Stockscreener-App
30.39
3.65%
1.07
Vorhandelsmarkt:
30.39
Schlusskurs vom Vortag:
$29.32
Offen:
$29.45
24-Stunden-Volumen:
961.16K
Relative Volume:
0.69
Marktkapitalisierung:
$2.90B
Einnahmen:
$70.79M
Nettoeinkommen (Verlust:
$-286.89M
KGV:
-8.6003
EPS:
-3.5336
Netto-Cashflow:
$-326.34M
1W Leistung:
+5.01%
1M Leistung:
+0.07%
6M Leistung:
+63.04%
1J Leistung:
+99.61%
1-Tages-Spanne:
$28.68
$30.69
1-Wochen-Bereich:
$26.31
$30.69
52-Wochen-Spanne:
$9.90
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Firmenname
Viridian Therapeutics Inc
Sektor
Branche
Telefon
617.272.4600
Adresse
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
30.39 | 2.80B | 70.79M | -286.89M | -326.34M | -3.5336 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Bestätigt | Wedbush | Outperform |
| 2025-12-03 | Eingeleitet | William Blair | Outperform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Eingeleitet | TD Cowen | Buy |
| 2024-09-11 | Bestätigt | Needham | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-05-09 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Eingeleitet | BTIG Research | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-04-17 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2022-12-19 | Eingeleitet | Cowen | Outperform |
| 2022-12-19 | Eingeleitet | Needham | Buy |
| 2022-12-16 | Eingeleitet | Credit Suisse | Outperform |
| 2022-12-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-18 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Propel Bio Management LLC Makes New Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment By Investing.com - Investing.com South Africa
Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment - Investing.com Australia
[144] Viridian Therapeutics, Inc.DE SEC Filing - Stock Titan
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
Viridian Therapeutics, Inc. $VRDN Position Increased by Fisher Asset Management LLC - MarketBeat
Viridian Therapeutics, Inc. (VRDN): Investor Outlook on a Biotech Powerhouse with 38% Upside Potential - DirectorsTalk Interviews
Viridian Therapeutics (VRDN) Balances Rising Losses With Veligrotug Milestones and New Employee Stock Shelf Registration - Sahm
What analyst consensus says on Viridian Therapeutics Inc. stockRisk Management & Free Growth Oriented Trading Recommendations - mfd.ru
How (VRDN) Movements Inform Risk Allocation Models - Stock Traders Daily
Royal Bank Of Canada Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - MarketBeat
Viridian Therapeutics (VRDN) Analyst Maintains Rating; Adjusts P - GuruFocus
RBC Adjusts Price Target on Viridian Therapeutics to $42 From $45, Maintains Outperform Rating - marketscreener.com
What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders - Yahoo Finance
VRDN Should I Buy - Intellectia AI
Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus
Jefferies Maintains Buy, PT $45 for Viridian Therapeutics (VRDN) Feb 2026 - Meyka
VRDN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Viridian Therapeutics (NASDAQ:VRDN) Releases Earnings Results, Misses Expectations By $0.18 EPS - MarketBeat
Jefferies raises Viridian Therapeutic stock price target on trial progress By Investing.com - Investing.com Canada
Viridian Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Wedbush Cuts Viridian Therapeutics Price Target to $44 From $47, Maintains Outperform Rating - marketscreener.com
Evercore ISI reiterates Viridian Therapeutic stock rating on data conviction By Investing.com - Investing.com Canada
Viridian Therapeutics earnings beat by $0.64, revenue topped estimates - Investing.com
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Viridian Therapeutics earnings missed by $0.10, revenue fell short of estimates - Investing.com UK
Viridian Therapeutics Q4 revenue misses analyst expectations - TradingView
Viridian Therapeutics Reports Q4 and Full Year 2025 Financial Results - TradingView
TED drug veligrotug nears FDA decision as Viridian (NASDAQ: VRDN) ramps spend - Stock Titan
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
Viridian Therapeutics (VRDN) TTM US$342.6 Million Loss Tests Bullish Growth Narratives - Sahm
Tech Rally: What is the implied volatility of Viridian Therapeutics IncTrade Exit Report & AI Optimized Trade Strategies - baoquankhu1.vn
Growth Review: Is Viridian Therapeutics Inc subject to activist investor interest2025 Price Momentum & Trade Opportunity Analysis - baoquankhu1.vn
VRDN PE Ratio & Valuation, Is VRDN Overvalued - Intellectia AI
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - The Motley Fool
Can Viridian Therapeutics Inc. stock double in the next year2025 Key Highlights & Real-Time Chart Breakout Alerts - mfd.ru
Can Viridian Therapeutics Inc. be the next market leader2025 Valuation Update & Long Hold Capital Preservation Plans - mfd.ru
Is Viridian Therapeutics Inc.’s ROIC above industry averageWeekly Risk Report & Free Community Supported Trade Ideas - mfd.ru
Viridian Preparing To Launch Its First Drug And A Fast Follower In TED - Citeline News & Insights
VRDN SEC FilingsViridian Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
What are Viridian Therapeutics Inc.’s earnings expectations2025 Valuation Update & Free Expert Approved Momentum Trade Ideas - mfd.ru
Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Viridian Therapeutics surveys impact of thyroid eye disease on daily life - Traders Union
Truist reiterates Viridian Therapeutic stock rating ahead of trial By Investing.com - Investing.com Canada
Viridian Therapeutics, Inc. (VRDN) Stock Analysis: A 50.75% Upside Potential In Biotech - DirectorsTalk Interviews
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Trading Systems Reacting to (VRDN) Volatility - Stock Traders Daily
Published on: 2026-02-13 20:43:42 - mfd.ru
What is the implied volatility of Viridian Therapeutics Inc.Weekly Investment Recap & Risk Managed Investment Strategies - mfd.ru
Viridian Therapeutics, Inc. (VRDN) Stock Analysis: 42% Potential Upside Amidst Breakthrough Biotechnology Advances - DirectorsTalk Interviews
Street Watch: What are the future prospects of Viridian Therapeutics IncJuly 2025 Catalysts & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):